体弱癌症患者相关血栓的抗凝治疗:虚弱因素对药物相互作用管理的影响
该综述聚焦体弱癌症合并血栓(CAT)患者,指出抗Xa直接口服抗凝药(DOACs)与化疗药存在大量药物相互作用,而体弱患者常被大型试验排除,现行指南不完全适用。作者识别年龄、合并症和合并用药为关键虚弱因素,并制定治疗决策算法以优化抗凝选择。
要点
- 抗Xa DOACs是CAT长期治疗的首选,但与化疗药相互作用可改变DOAC水平,增加出血或血栓复发风险。
- 体弱患者因多重合并症常被大型试验排除,指南不完全适用,需个案化风险评估。
- 年龄、合并症和合并用药是需重点关注的虚弱关键因素,应结合癌症类型评估出血风险并预判相互作用强度。
核心结论
- 体弱CAT患者的抗凝管理复杂,需基于癌症类型、患者相关危险因素和药物相互作用进行个案化风险评估以优化抗凝选择。
研究设计与样本
- 简要综述,基于随机对照试验证据及文献报告,识别虚弱关键因素并制定治疗决策算法。
主要发现
- DOACs与化疗药之间存在大量药物相互作用,可改变DOAC循环水平,引发对出血风险增加或血栓复发的担忧。
- 体弱患者因多重合并症常被大型试验排除,当前指南不完全适用于该人群。
- 年龄、合并症和合并用药被识别为需仔细关注的虚弱关键因素。
关键数值与推荐
- 抗Xa DOACs被视为CAT治疗的首选。
- 低分子量肝素(LMWH)和抗Xa DOACs基于充分记录的随机对照试验被推荐用于CAT长期治疗。
临床怎么用
- 根据癌症类型评估出血风险,预判药物相互作用强度,并结合患者虚弱因素优化抗凝选择。
- 肿瘤科医生、血管病理专科医生和药师之间需系统协作以确保最佳患者管理。
局限性
- 需临床研究确定这些相互作用的真实影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Low molecular weight heparins (LMWH) and anti-Xa direct oral anti-coagulants (DOACs) are recommended for the long-term treatment of cancer-associated thrombosis (CAT) based on well-documented randomised controlled trials. Anti-Xa DOACs are viewed as a first choice for the treatment of patients with CAT. A large number of drug-drug interactions have been reported between DOACs and chemotherapy drugs, modifying circulating levels of DOAC leading to fears of increased bleeding risks or thrombotic recurrence. Progresses in anti-neoplastic therapies have improved the prognosis and the survival, thus increasing the prevalence of frail patients with cancer. However, since frailties tend to be excluded from large trials due to multiple co-morbidities, current guidelines are not fully applicable to this population. The management of these frail patients with CAT is particularly complex and requires a risk assessment on a case-by-case basis with specific focus on cancer, patient-related risk factors and drug-drug interactions. In this brief review we have identified age, co-morbidities and co-medications as key factors of frailty that require careful attention and we have developed a therapeutic decision algorithm to help clinicians optimising the use of anti-coagulants in patients with cancer with CAT, especially in case of anti-Xa DOACs concomitant medications. With the evaluation of the bleeding risk according to the type of cancer, and anticipating drug-drug interactions intensity, taking into account patient frailties allows the optimisation of the anti-coagulant choice. A systematic collaboration between oncologists, vascular pathology specialists and pharmacists is warranted to ensure an optimal patient management. Clinical studies are needed to determine the real impact of these interactions.
引用
- Grange C, Rioufol C, Souquet PJ, et al. Anti-coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug-Drug Interactions. Clin Pharmacokinet. 2023. PMID: 37824026. doi:10.1007/s40262-023-01298-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。